Biocartis Group NV: Disclosure of a transparency notification
(Thomson Reuters ONE) -
PRESS RELEASE: REGULATED INFORMATION
14 November 2017, 07:00 CET
Disclosure of a transparency notification
(Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major
shareholdings)
Mechelen, Belgium, 14 November 2017 - Biocartis Group NV (the 'Company' or
'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels:
BCART), announces today in accordance with Article 14, paragraph 1 of the
Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers
whose shares are admitted to trading on a regulated market (the 'Belgian
Transparency Act'), that it received a transparency notification dated 10
November 2017 (the 'Notification'), indicating that as a result of the disposal
of voting securities on 7 November 2017, TopBio1 LP crossed the lowest
notification threshold of 3%. As a result, TopBio1 LP no longer holds voting
securities or voting rights in Biocartis.
The Notification contains the following information:
· Reason for the Notification: Downward crossing of the lowest threshold.
Acquisition or disposal of voting securities or voting rights.
· Notification by: A person that notifies alone.
· Persons subject to the notification requirement: TopBio1 LP, 89 Nexus Way,
2(nd) Floor, Camana Bay, P.O. Box 31106, Grand Cayman, KY1-1205 Cayman Islands.
· Transaction date: 7 November 2017.
· Threshold that is crossed: 3%.
· Denominator: 44,669,772.
· Details of the Notification: TopBio1 LP no longer holds voting securities
or voting rights in Biocartis.
· Chain of controlled undertakings through which the holding was effectively
being held: TopBio1 LP is not a controlled entity.
The Notification is available here on the website of the Company.
Pursuant to the Belgian Transparency Act and the articles of association of the
Company, a notification to the Company and the Belgian Financial Services and
Markets Authority ('FSMA') is required by all natural and legal persons in each
case where the percentage of voting rights in the Company held by such persons
reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every
subsequent multiple of 5%, of the total number of voting rights in the Company.
----- END ----
More information:
Renate Degrave
Manager Corporate Communications & Investor Relations Biocartis
email rdegrave(at)biocartis.com
tel +32 15 631 729 | mobile +32 471 53 60 64
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis offers ten oncology tests and two infectious
disease tests in Europe. More information: www.biocartis.com. Press Photo
Library available here. Follow us on Twitter: (at)Biocartis_.
The Biocartis trademark and logo are trademarks of Biocartis and are used and
registered in Europe. Idylla(TM) is a registered trademark in the United States
and other countries. The Idylla(TM) trademark and logo are trademarks of and
used by Biocartis. This press release is not for distribution, directly or
indirectly, in any jurisdiction where to do so would be unlawful. Any persons
reading this press release should inform themselves of and observe any such
restrictions. Biocartis takes no responsibility for any violation of any such
restrictions by any person. Please refer to the product labeling for applicable
intended uses for each individual Biocartis product. This press release does not
constitute an offer or invitation for the sale or purchase of securities in any
jurisdiction. No securities of Biocartis may be offered or sold in the United
States of America absent registration with the United States Securities and
Exchange Commission or an exemption from registration under the U.S. Securities
Act of 1933, as amended.
Forward-looking statements
This press release may contain forward-looking statements. Such forward-looking
statements are not guarantees of future performance. These forward-looking
statements speak only as of the date of this press release. Biocartis expressly
disclaims any obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release. You should not place undue
reliance on forward-looking statements.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.11.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 567942
Anzahl Zeichen: 6313
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 294 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: Disclosure of a transparency notification"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
